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ABSTRACT 
 
Background: Multidrug-resistant (MDR) tuberculosis (TB) in children is frequently associated with delayed 
diagnosis and treatment. There is limited evidence regarding the management and outcome of children with 
MDR-TB. 
 
Methods: All children less than 15 years of age diagnosed with culture-confirmed MDR-TB were included in 
this retrospective cohort study from 1st January 2003 to 31st December 2008, with follow up documented 
until 31st May 2011. We identified children from Brooklyn Hospital for Chest Diseases and Tygerberg 
Children’s Hospital, Western Cape Province, South Africa. Treatment outcomes were defined as two month 
sputum culture-conversion, treatment episode outcome and survival. 
 
Results: 111 children (median age 50 months) were included. The diagnosis was delayed in children who had 
no identified MDR-TB index case (median 123 vs. 58 days; p<0.001). Sixty-two percent (53/85) were sputum 
smear positive and 43% (43/100) were HIV-infected. Overall, 82% had favorable treatment outcomes; total 
mortality was 12%. Malnutrition was associated with failure to culture-convert at two months (OR: 4.49 [CI: 
1.32-15.2]; p=0.02) and death (OR: 15.0 [CI: 1.17-192.5]; p=0.04) in multivariate analysis. HIV co-infection 
(OR: 24.7 [CI: 1.79-341.1]; p=0.02) and the presence of extrapulmonary TB (OR: 37.8 [CI: 2.78-513.4]; 
p=0.006) predicted death. 
 
Conclusions:  Despite advanced disease at presentation and a high prevalence of HIV co-infection, children 
with MDR-TB can be treated successfully using individualized treatment under routine conditions.   
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INTRODUCTION 
 
Multidrug-resistant (MDR) tuberculosis (TB) is caused by Mycobacterium tuberculosis (M. tuberculosis) 
resistant to isoniazid and rifampin. World Health Organization (WHO) estimated that there were 440,000 
new MDR-TB cases world-wide during 2008.[1] Treatment outcomes are generally poor in adults, with 
favorable outcomes  reported in only 60% of those receiving  treatment.[2] Even though childhood TB 
comprises approximately 15-20% of the global TB burden,[3] MDR-TB is poorly studied in children, the  
literature including mainly case reports or small case series.[4-16]  
 
The diagnosis of TB in young children is challenging and often delayed.[17] Symptoms and signs may be non-
specific, especially in children younger than three years of age and in children infected with human 
immunodeficiency virus (HIV). [18] Due to the paucibacillary nature of childhood TB, a microbiological 
diagnosis is typically made in only 20-40% of cases with radiological evidence of intrathoracic disease.[19] 
Since drug susceptibility testing (DST) is only possible following bacteriological confirmation, confirmed 
MDR-TB in children is infrequent. In the absence of a known MDR-TB source case, children are often initially 
treated for drug-susceptible TB and MDR-TB treatment started only once treatment is failing, microbiology 
and DST results become available, or an MDR-TB source case is identified.  
 
Treating children with MDR-TB is complex. Few of the multiple drugs routinely used to treat MDR-TB have 
been studied in children and guidance on drug regimens, dosages, appropriate monitoring and duration of 
therapy is frequently extrapolated from adult data. As young children metabolize drugs more rapidly than 
adults and generally have paucibacillary disease,[20] this may not  always be appropriate. We describe the 
clinical presentation, treatment and outcome of a large cohort of children with confirmed MDR-TB and 
evaluate factors influencing treatment response. 
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METHODS 
 
Setting and population 
This retrospective cohort study was conducted in the Western Cape Province,  South Africa, where the TB 
notification rate was 978 per 100,000 in 2009.[21] Amongst all children with routinely diagnosed culture-
confirmed TB at Tygerberg Children’s Hospital (TCH) during 2005-2007, 6.7% were identified as MDR.[22]  In 
this setting, children initially present to a variety of regional primary (community-based) health clinics and 
referral hospitals while TCH serves as the main referral centre for children with drug-resistant TB exposure 
or disease.  Once stable on treatment, children are managed at the Brooklyn Hospital for Chest Diseases 
(BHCD), a specialist TB hospital. After discharge, children are routinely followed as outpatients at TCH. 
 
Eligibility criteria 
Children less than 15 years of age were included if they were diagnosed with confirmed MDR-TB between 1st 
January 2003 and 31st December 2008. DST on all children with culture-confirmed TB was routine during the 
study period. Follow up was documented until 31st May 2011. 
 
Mycobacterial culture and drug susceptibility testing 
Mycobacterial culture was completed at the accredited National Health Systems Reference Laboratory 
following a standard protocol to prevent mycobacterial cross-contamination. Primary mycobacterial cultures 
were established by inoculation of routine clinical samples into Middlebrook 7H9 broth-based Mycobacterial 
Growth Indicator Tubes (MGIT960; Becton Dickinson, Sparks, MD, USA) following a standard protocol for 
decontamination, while lymph node aspirates, pleural fluid, cerebrospinal fluid and other bodily fluids were 
directly inoculated. M. tuberculosis complex isolates were confirmed through PCR.[23] Phenotypic DST was 
performed using two different assays which have been shown to yield highly concordant results as 
previously described.[24]  
 
P a g e  | 6 
Definition of TB episodes and treatment delay 
A previous TB episode was defined as standard TB treatment (isoniazid, rifampin and pyrazinamide with or 
without ethambutol) for at least one month, followed by a symptom-free period of ≥ 6 months (reported by 
parent/carer and the absence of presentations to any health care providers) before the start of the current 
MDR-TB episode; a commonly used programmatic definition of a separate episode.[25] A MDR-TB episode 
was defined as beginning (if MDR-TB was subsequently confirmed) at the child’s initial documented 
presentation to the health care system, when the specimen was obtained confirming MDR-TB, or when TB 
treatment was commenced. Treatment delay was defined as time from the start of MDR-TB episode to 
initiation of MDR-TB treatment. Treatment delay could not be determined in children who died or were lost 
to follow-up prior to start of MDR-TB treatment, and for those treated inadvertently with first-line drugs 
only. 
 
Clinical data and standard of care  
MDR-TB treatment was based on local standard of care, informed by international recommendations and 
available literature.[26-33]  High-dose (15-20mg/kg) isoniazid was used in the majority of cases, as there is 
evidence that isolates with an inhA promoter region mutation usually have a low minimum inhibitory 
concentration (MIC).[34] An injectable agent, most frequently amikacin (15-30mg/kg), was typically used for 
six months; capreomycin (15-30mg/kg) was substituted if resistance to amikacin was detected. Ofloxacin 
(15-20mg/kg), the most effective fluoroquinolone available in the South African National TB Programme, 
was used. Further drugs were added to result in at least four effective drugs. These included: ethionamide 
(15-20mg/kg), para-aminosalicylic acid (PAS; 150mg/kg), terizidone (10-20mg/kg), co-amoxiclavulanic acid 
(10-15mg/kg 8 hourly), clarithromycin (7.5-15mg/kg 12 hourly) and linezolid (10mg/kg twice daily). All 
antituberculosis drugs were given as directly observed therapy (DOT) for the full treatment duration. Most 
children remained hospitalized during the intensive phase when an injectable was given. Thereafter, children 
were treated at their local TB clinic with hospital out-patient follow-up every two months. Children with 
extensively drug-resistant TB (XDR; MDR-TB with resistance to a fluoroquinolone and a second-line 
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injectable agent), were treated for longer periods, typically for 24 months. If not yet on combination 
antiretroviral therapy (cART), cART was started in HIV-infected children after the initiation of MDR-TB 
treatment, consistent with national guidelines. 
 
Clinical data collection  
Data were collected through chart review. HIV testing followed written informed consent from the parent or 
legal guardian with pre- and post-test counseling using ELISA in children >18 months and DNA PCR test in 
younger and breast-fed children. Immunological staging in HIV-infected children used the WHO 
classification.[35] Weight was recorded and plotted on National Centre for Health Statistics weight-for-age 
percentile chart. Malnutrition was classified as weight <3rd percentile for age. Two tuberculin units were 
injected intradermally (purified protein derivative RT23, Statens Serum Institute) for tuberculin skin testing 
(TST). Results were read at 48-72 hours with a transverse diameter of ≥10mm considered positive in HIV-
uninfected and ≥5mm in HIV-infected children. TB disease severity was defined using chest radiograph (CR) 
features following review by a single expert reader, read systematically with standardized recording.[36] 
Disease was classified as pulmonary if there were any CR changes attributable to TB or if any thoracic 
samples were positive for M. tuberculosis. Extra-pulmonary disease (EPTB) was classified if any imaging 
(ultrasound, plain film radiology or computerized tomography) demonstrated extra-thoracic TB or if a 
microbiological sample confirmed TB from a site other than the lungs. Intra-thoracic radiological features 
were classified as non-severe (normal, hilar lymphadenopathy, airway compression, lobar/segmental 
collapse/opacification or pleural effusions) and severe (cavities, miliary opacification or a widespread 
bronchopneumonic picture).   
 
Outcome 
Respiratory samples in children with pulmonary involvement were obtained monthly to monitor response to 
therapy.  Standard international definitions of final treatment outcome were used, with minor adaption for 
children.[37] The definition of cure for adults with MDR-TB is completion of  treatment with five negative 
P a g e  | 8 
cultures in the final twelve months of treatment.[26] For children with drug-susceptible TB, cure is defined 
as being sputum culture or smear-negative in the last month of treatment and on at least one previous 
occasion.[27] Cure for this study was defined as three consecutive negative respiratory cultures obtained at 
least one month apart with no positive cultures after the first negative result, in the presence of treatment 
completion. Treatment outcomes were further classified as favorable (cured and treatment completed) or 
unfavorable (died, lost to follow-up, treatment failure, transferred out). For MDR-TB episodes with an initial 
sputum positive culture, culture-conversion was defined as the time from initiation of therapy until the first 
negative culture, provided there were no subsequent positive cultures and at least two further negatives. 
We describe two-month culture-conversion as it is a frequently-used surrogate marker for final treatment 
outcome in adult treatment trials.[38] We further describe the total proportion of children who died. 
 
Statistical analysis 
Data were analyzed using STATA version 11. All identifier details were dissociated from clinical data by 
unique study numbers. Missing data were excluded from analysis. Continuous variables were used for age 
and delay. Associations between clinical characteristics at presentation were assessed using the χ2 test (or 
Fisher’s exact test) when comparing categorical data; effect estimates (odds ratios; OR) and 95% confidence 
intervals (CI) were calculated. The Mann -Whitney test was used to assess the effect of age and delay given 
the non-normal distribution of the data. Risk factors for treatment outcomes (two-month culture-
conversion, final treatment outcome and death) were assessed in univariate analysis. Multivariate logistic 
models were used to analyze the relationship between presenting characteristics and outcomes if either the 
univariate relationships showed significance (p<0.05) or where variables were thought to be clinically or 
epidemiologically relevant. Variables classified as collinear were not used in combination in the model. 
 
This study was approved by the Committee for Human Research, Stellenbosch University and the London 
School of Hygiene and Tropical Medicine (waiver of informed consent obtained). 
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RESULTS 
 
During the study period, 111 children with MDR-TB were identified with a median age of 50 months (inter-
quartile range [IQR] 19-108); all were included. Forty-two samples underwent DST to second-line drugs 
which identified three MDR-TB cases resistant to amikacin, four resistant to ofloxacin and five to both 
ofloxacin and amikacin (XDR-TB). An overview of the cohort with treatment outcomes is provided in Figure 1. 
Demographic and clinical characteristics at the start of MDR-TB treatment are described in Table 1. The 
median time to MDR-TB treatment initiation (n=102) was shorter in the presence of a known adult MDR-TB 
index case (median 58 days [IQR 25-120] vs. 123 days [IQR 67-231]; p<0.001). Fifty-three of 85 (62%) children 
with a sputum result were smear positive; a positive sputum smear was more common in older children 
(median 85 months [IQR 25-132] vs. 24 months [IQR 15-59]; p<0.001) and in children with more severe CR 
changes (OR 9.95 [CI 2.98-33.3]; p<0.001). Of children HIV-tested (n=100, 90.1%), 43 (43%) were positive; 27 
(64%) had severe immune suppression.  Nineteen children were on cART prior to initiation of MDR-TB 
treatment; 21 were started afterwards (median time to initiation: 75 days [IQR 18-123]). Fifty children 
(n=109; 46%) had severe CR changes at diagnosis; children with severe CR changes were older (median 84 
months [IQR 27-121] vs. 28 months [IQR 15-68]; p=0.002) [table1] 
 
Of the 111 cases, 91 (82%) had a favorable treatment outcome. Of these, three were treated successfully 
with only first-line drugs: two had cervical lymph node disease and the other only hilar lymphadenopathy. 
Four patients were transferred to another hospital and three were lost to follow -up. One adolescent, 
diagnosed with pulmonary XDR-TB, was a repeat defaulter and her sputum never converted. She was 
declared a treatment failure after two years of intermittent treatment and eventually transferred into adult 
care. One patient was still on treatment at the end of the study period, having been initially treated for 
MDR-TB with additional resistance to amikacin according to his bacteriology, and then as XDR-TB based on 
his mother’s bacteriology. The overall mortality was 12% (13 deaths; Table 2) regardless of treatment 
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initiation. Eleven children died during their MDR-TB episode, one was cured of TB but died in the year 
following the end of treatment and one died following treatment failure. 
 
Of the 88 cases successfully treated with MDR-TB drugs, 79 (89.8%) were alive and well at twelve months 
after completion of treatment. Of the remaining nine, three had been transferred to another institution, five 
had been lost to follow-up and one had died. Those successfully treated were treated for a median of 18 
months, including median six months on an injectable, and were treated with a median of seven drugs over 
the total course of treatment. (Table 3) 
 
Univariate analysis of clinical features and their association with outcome are shown in Table 4. Malnutrition 
and severe CR changes were associated with a failure to culture-convert by month two, unsuccessful 
treatment outcome and death. HIV infection and EPTB were associated with death. Children with positive 
smears at diagnosis were less likely to have culture-converted by month two. Multivariable analysis is shown 
in Table 5. After adjustment for age and smear status (or CR severity), malnutrition at diagnosis predicted 
failure to culture-convert by two months (OR: 4.49 [CI: 1.32-15.2]; p=0.02). Malnutrition (OR: 15.0 [CI: 1.17-
192.5]; p=0.04), HIV infection (OR: 24.7 [CI: 1.79-341.1]; p=0.02) and EPTB (OR: 37.8 [CI: 2.78-513.4]; 
p=0.006) all independently predicted mortality in a model adjusting for age. 
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DISCUSSION 
 
We document the clinical presentation, treatment and outcomes of children with culture-confirmed MDR-TB 
under routine clinical conditions in a high TB-burden setting. To our knowledge, this is the largest cohort of 
children with culture-confirmed MDR-TB described to date. Our data indicate that children with culture-
proven MDR-TB tend to be young, malnourished, are frequently HIV-infected and often present with 
radiological features of advanced disease. Furthermore, the absence of a known MDR-TB source case led to 
considerable delay in initiation of appropriate therapy. Treatment regimens were long (median 18 months) 
of which six months included an injectable. 
 
Of key importance is that, despite advanced disease and the presence of EPTB in more than 30%, the 
majority were treated successfully, with more than 80% favorable outcomes. We identify important risk 
factors for clinically and programmatically relevant treatment outcomes including mortality. HIV, 
malnutrition and extrapulmonary involvement were independent risk factors for death in adjusted analyses.  
Five of the 13 deaths occurred before MDR-TB was confirmed and appropriate treatment started indicating 
the importance of early diagnosis. Although severe disease on CR was associated with all outcome measures 
in univariate analyses, this association was less pronounced in adjusted analyses. Our findings suggest that, 
once identified and treated appropriately with individualized therapy based on available DST, children with 
MDR-TB have a good prognosis, even with high prevalence of HIV co-infection.  
 
Other reports of MDR-TB in children include a previous study from Cape Town of 39 children with culture-
confirmed disease; similar to the present study, treatment delay was common if an MDR index case was not 
identified.[4] A study from Peru described 38 children treated for MDR-TB, 28 with confirmed disease, and 
also found considerable delay in the initiation of appropriate therapy.[5] A study from New York of 20 
children treated for MDR-TB (six culture-confirmed), demonstrated good outcomes and minimal toxicity.[6] 
A recent case series of 13 children with culture-confirmed MDR-TB from Johannesburg (54% HIV-infected) 
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indicated high mortality of 30%.[12] Other case reports and small series are reported from other settings. [7-
11, 13-16] Despite the delay in diagnosis, severe disease at presentation and the need for second-line 
medications, these studies all describe good outcomes, in dramatic contrast to adult MDR-TB data.[2] 
Reasons for this contrast are unclear. Children may have less severe and paucibacillary disease, may tolerate 
and adhere to medications better, may be less frequently HIV-infected or may have less concomitant 
pathology. Further research is required in this field. 
 
The absence of an identified adult MDR-TB index case was strongly associated with delay in initiation of 
appropriate treatment in children. Of note, there were 16 (14.4%) children who had an index case 
documented to have died, failed treatment or who was a re-treatment case, indicating a high MDR risk 
exposure. These factors highlight the importance of careful history taking from both the child’s caregiver and 
health services regarding adults with known MDR-TB or with known risk factors for MDR-TB.  
 
Since we only report on children with culture-confirmed disease, our data are not representative of all 
children with MDR-TB, many of whom are treated on the basis of MDR-TB contact history or poor clinical 
response to therapy. As  bacteriologic yield is associated with radiological extent of disease,[19] we likely 
report children with more advanced disease. Since we report on children diagnosed with MDR-TB using 
combined sources of surveillance (laboratory and TB register sources), we do not report on only those who 
started therapy (the traditional TB treatment cohort approach). Given this conservative approach, we 
probably under-estimate treatment success in our cohort. The long duration of treatment (median of six 
months with a second-line injectable medication and 18 months overall) could possibly be reduced in 
children with less severe disease in future, if adequate evidence from clinical studies becomes available. 
 
In our study, many children had severe disease at initiation of treatment. There was a high proportion with a 
positive smear and nearly half had cavities, severe bronchopneumonic changes or a miliary opacification on 
CR.  Young children are traditionally considered to have paucibacillary TB and as they generally have a poor 
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tussive force, are considered to pose low infection risk. However, our data indicate that children with 
culture-confirmed MDR-TB frequently have severe disease, are somewhat older than those with drug-
susceptible TB,[22, 39] and coupled with high rates of smear-positivity may prove a greater infection risk 
than previously thought. Infection control should be an important consideration in the management of 
children with MDR-TB.   
 
This retrospective study has limitations including reliance on routine data. We did not have systematic data 
regarding adverse effects and the tolerability of multiple medications, frequently unpalatable, was not 
systematically assessed. Although all samples were confirmed MDR, DST to second-line drugs was not 
routinely completed during the study period. We have reported the second-line DST results that were 
available but due to inconsistent testing and significant bias in completion of DST we are unable to draw 
meaningful conclusions. Finally, although treatment outcomes were good, we do not comment on morbidity 
as a result of MDR-TB disease and treatment. All of these aspects need assessment in future prospective 
studies. 
 
In conclusion, although South African children with confirmed MDR-TB often present with severe disease 
and are frequently HIV-infected, excellent treatment outcomes can be achieved in high-burden settings with 
individualized clinical care under standard programmatic conditions.  
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Table 1. Clinical characteristics at initial presentation in children with bacteriologically confirmed MDR-TB (n=111*) 
 
Characteristic  Description Number 
(percentage)1 
Age  Median months (IQR) 50 (19-108) 
Male gender   46 (41.4) 
Treatment delay (n=105) Median days (IQR) 91 (51-166) 
Index case None identified 33 (29.7) 
Index case identified with no evidence of MDR-TB 17 (15.3) 
MDR-TB index case indentified 45 (40.5) 
Index case defaulter, treatment failure or died 16 (14.4) 
Previous treatment episode   28 (25.2) 
Positive Mantoux test (n=89)  63 (70.8) 
Weight  <3rd percentile for age 41 (36.9) 
3rd – 10th percentile for age 28 (25.2) 
>10th percentile for age 42 (37.8) 
Type of TB  PTB only 73 (65.8) 
EPTB only 12 (10.8) 
Both PTB and EPTB 26 (23.4) 
Site of EPTB (n=38) (>1 site 
possible) 
Miliary 7 (18.4) 
Tuberculous meningitis 6 (15.8) 
Pericardial effusion 2 (5.3) 
Pleural effusion 7 (18.4) 
Abdominal 8 (21.1) 
Peripheral lymph node 16 (42.1) 
Bone/joint/spine 9 (23.7) 
Ear 5 (13.2) 
Sputum smear positive (n=85)  53 (62.3) 
Drug susceptibility test pattern 
(n=42) 
MDR 30 (71.4) 
MDR with resistance to amikacin 3 (7.1) 
MDR with resistance to ofloxacin 4 (9.5) 
XDR 5 (11.9) 
CR features (n=109) (> 1 feature 
present in the majority) 
Normal CXR (all had EPTB) 11 (10.1) 
Hilar lymphadenopathy or airways compression 52 (47.7) 
Lobar/segmental collapse/opacification 76 (69.7) 
Large pleural effusion 7 (6.4) 
Cavities 38 (34.9) 
Miliary opacification 7 (6.4) 
Widespread bronchopneumonic changes 21 (19.2) 
CR severity (n=109) 
 
Non-severe 59 (54.1) 
Severe 50 (45.9) 
Time to sputum conversion (n=74) Median months (IQR) 2 (1-3) 
HIV-infected (tested n=100)  43 (43.0) 
HIV immunological stage (n=42) Not significant2 7 (16.7) 
Mild3 5 (11.9) 
Moderate4 3 (7.1) 
Severe5 27 (64.3) 
When started on cART (n=43) Never (all died) 3 (7.0) 
Already on cART at start of MDR TB episode 9 (20.9) 
Started on cART between start of episode and start of 
MDR-TB treatment 
10 (23.3) 
After start of MDR-TB treatment 21 (48.8) 
Time from start of MDR-TB 
treatment to cART initiation  (n=21) 
Median days (IQR) 75 (18-123) 
 
1unless otherwise stated 
2 CD4 value: <11 months: >35%; 12-35 months: >30%; 36-59 months: >25% & >5 years: >500 cells/mm3 
3CD4 value: <11 months: 30-35%; 12-35 months: 25-30%; 36-59 months: 20-25% & >5 years: 350-499 cells/mm3  
4CD4 value: <11 months: 25-29%; 12-35 months: 20-24%; 36-59 months: 15-19% & >5 years: 200-349 cells/mm3 
5CD4 value: <11 months: <25%; 12-35 months: <20%; 36-59 months: <15% & >5 years: <200 cells/mm3 or <15%
   
Table 2. Description of deaths (N=13) in children with culture-confirmed MDR-TB (n=111) 
 
Age at 
death 
Gender HIV status CD4 
count 
(%) 
Site of disease History Attributed cause of death 
11 years  Male Unknown  Spinal Presented with severe disease, underwent surgery and biopsy 
sample taken, started on first-line treatment but died one month 
later prior to diagnosis being made 
MDR-TB of the spine 
6 months Male Positive 1652  
36% 
Pulmonary TB Died after one month on first-line therapy, MDR-TB diagnosed  
posthumously only 
Hepatotoxicity, HIV, MDR-TB, Down’s syndrome, severe 
cardiac defect, marasmic, bacterial pneumonia 
10 years Female Positive 37  
8% 
Disseminated (miliary) Died after 12 months of MDR-TB treatment Developed disseminated TB including TB meningitis 
whilst on full MDR-TB treatment in hospital. Possible 
XDR-TB 
6 years Male Positive 33 
2% 
Pulmonary and 
abdominal TB 
Treated for 10 months with first-line drugs before sample sent for 
culture. MDR-TB diagnosed posthumously only  
Disseminated MDR-TB 
9 months Male Positive 825 
19% 
Pulmonary, miliary and 
lymph node TB 
Died after three months of MDR-TB treatment Multi-system failure, HIV, extensive disseminated TB 
disease at presentation, sepsis, heart failure, 
thrombocytopenia 
4 years Female Positive Not 
tested 
TB meningitis Died after three months of MDR-TB treatment Severe TB meningitis (stage 3) 
12 months Female Positive 117 
6% 
Pulmonary TB Died after five months of MDR-TB treatment Severe HIV, systemic candida infection, osteomyelitis, 
respiratory failure, pneumonia, S. aureus sepsis 
2 years Female Negative  TB meningitis, 
pulmonary, abdominal 
and lymph node TB 
Died after one month first-line treatment, MDR-TB diagnosed after 
death 
Disseminated MDR-TB meningitis 
15 years Female Unknown  Pulmonary TB Died after one month MDR-TB treatment, pre-XDR result returned 
after death 
Congenital myopathy, aplastic anaemia, requiring 
multiple transfusions, extensive pre-XDR-TB 
2 years Male Positive 1065 
26% 
TB meningitis Given 24 days first-line treatment for stage three, TB meningitis prior 
to MDR-TB diagnosis. Died after one month MDR-TB treatment  
MDR-TB meningitis, HIV 
8 years Female Unknown  Pulmonary TB Spastic quadriplegia from previous illness, died 6 days after starting 
first-line treatment, MDR-TB diagnosed after death 
Severe MDR-TB, pre-existing neurological condition 
making diagnosis challenging 
12 years Female Negative  Pulmonary TB Adolescent repeated defaulter with pre-XDR TB. Never sputum 
culture-converted and declared a treatment failure after 12 months 
of MDR-TB treatment. Transferred to adult care 
Died of pre-XDR TB under the care of adult physician 
8 years Female Negative  Pulmonary TB Registered as cured of MDR-TB with 20 months of therapy. 
Significant lung damage as a result of TB 
Developed bronchiectasis and chronic lung abscess. 
Died within a year of finishing MDR-TB treatment with a 
bacterial infection. 
   
Table 3. Treatment characteristics in children successfully treated with an MDR-TB regimen (n=88*) 
 
Median number of drugs used at any point during treatment (range) 7 (4 – 13) 
Median duration of intensive phase therapy  (range) 6 (0 – 18)** 
Median total duration of therapy (range) 18 (8 – 26) 
Number of patients using anti-TB drugs 
(percentage) 
Isoniazid (high-dose) 83 (94.3) 
Rifampin 14 (15.9) 
Pyrazinamide 81 (92.0) 
Ethambutol 82 (93.2) 
Streptomycin 1 (1.1) 
Amikacin 80 (90.9) 
Capreomycin*** 6 (6.8) 
Ofloxacin 86 (97.7) 
Ethionamide 86 (97.7) 
Terizidone or cycloserine 57 (64.8) 
PAS*** 7 (8.0) 
Clarithromycin 7 (8.0) 
Augmentin 6 (6.8) 
Linezolid*** 2 (2.3) 
 
* With percentage unless stated otherwise 
** No injectable used in six cases 
*** Available only from 2007 
 
   
Table 4. Univariate analysis of clinical features, two month culture-conversion, treatment outcome and death in children with MDR-TB 
Characteristic  Failure to culture-convert by month two Unfavourable treatment outcome Deaths 
Number 
analyzed  
 
Number 
failing to 
convert 
Odds ratio (95% CI) P-value Number 
analyzed  
 
Number 
unfavourable 
outcome 
Odds ratio (95% CI) P-value Number 
analyzed 
Number 
dying 
Odds ratio (95% CI) P-value 
Age  74 
 
26  0.06 111 
 
20  0.80 111 11  0.97 
Gender Female 
 
46/74 13   65/111 10   65/111 6   
Male 28/74 
 
13 2.20 (0.80-6.01) 0.11 46/111 
 
10 1.53 (0.57-4.07) 0.39 46/111 5 1.20 (0.34-4.22) 0.78 
Nutrition ≥3rd percentile 53/74 
 
14   70/111 8   70/111 2   
<3rd percentile 21/74 12 3.71 (1.22-11.3) 0.01 41/111 12 3.21(1.15-8.96) 0.02 41/111 9 9.56 (1.79-51.2) 0.001 
HIV Negative 42/71 
 
14   57/100 7   57/100 1   
Positive 29/71 
 
11 1.22 (0.45-3.31) 0.69 43/100 10 2.16 (0.74-6.36) 0.15 43/100 7 10.9 (1.17-101.0) 0.008 
Timing of 
cART 
initiation 
Before MDR-
TB treatment 
14/29 4   22/43 5   22/43 4   
After MDR-TB 
treatment 
15/29 7 2.19 (0.44-10.8) 0.32 21/43 5 1.06 (0.25-4.45) 0.93 21/43 3 0.75 (0.14-3.92) 0.73 
Mantoux skin 
test  
Negative 16/62 
 
2   26/89 7   26/89 3   
Positive 46/62 
 
28 4.50 (0.85-23.7) 0.05 63/89 8 0.39 (0.12-1.27) 0.10 63/89 5 0.66 (0.14-3.03) 0.59 
MDR-TB 
contact 
No contact 35/74 
 
13   66/111 15   66/111 8   
Contact 39/74 
 
13 0.85 (0.32-2.21) 0.73 45/111 5 0.43 (0.14-1.29) 0.12 45/111 3 0.52 (0.13-2.09) 0.35 
Treatment 
delay  
 74 
 
26  0.25 103 15  0.36 103 8  0.18 
Site of TB No EPTB 60/74 
 
20   73/111 10   73/111 3   
EPTB 14/74 
 
6 1.50 (0.45-4.97) 0.50 38/111 10 2.25 (0.83-6.11) 0.10 38/111 8 6.22 (1.45-26.6) 0.005 
Smear status   Negative 27/68 
 
4   32/85 4   32/85 2   
Positive 41/68 
 
20 5.48 (1.47-20.4) 0.004 53/85 10 1.63 (0.46-5.77) 0.443 53/85 5 1.56 (0.28-8.68) 0.61 
CR severity Non-Severe 39/74 
 
9   59/109 5   59/109 2   
Severe 
 
35/74 17 3.15 (1.11-8.92 0.022 50/109 13 3.79 (1.20-12.0) 0.014 50/109 8 5.43 (1.05-28.2) 0.02 
   
Table 5. Multivariate analysis of clinical and bacteriological features at diagnosis, two month culture-conversion, treatment outcome and death in children with MDR-TB 
 
Characteristic Number in analysis OR (95% CI) P value
Failure to culture-convert by two months* 
Smear positivity  68 3.24 (0.82 – 12.8) 0.10
Malnutrition 68 4.49 (1.32 – 15.2) 0.02
Age  68 0.15
 
Poor treatment outcome** 
Severe CR changes 99 2.50 (0.68 – 9.19) 0.17
Malnutrition 99 1.87 (0.58 – 6.07) 0.30
HIV positivity 99 1.46 (0.46 – 4.63) 0.52
Age 99 0.51
 
Death 
EPTB 99 37.8 (2.78 – 513.4) 0.006
Malnutrition 99 15.0 (1.17 – 192.5) 0.04
HIV positivity 99 24.7 (1.79 – 341.1) 0.02
Age 99 0.18
 
* In an alternative model, holding all variables constant but replacing smear positivity with CR severity, findings were similar (n=74; severe CR changes: OR: 1.88 [CI: 0.61-5.78]; p=0.270, malnutrition: 
OR: 3.51 [CI: 1.12-11.0]; p=0.031, age: p=0.148) 
 
** In an alternative model, holding all variables constant but replacing severe CR changes with EPTB, findings were similar (n=100; EPTB: OR: 2.59 [CI: 0.86-7.75]; p=0.90, malnutrition: OR: 2.43 [CI: 0.80-
7.40]; p=0.115, HIV positivity: OR: 2.43 [CI: 0.65-5.98]; p=0.232, age: p=0.679) 
 
   
 
 
Figure 1. 
 
Overview of treatment outcomes in 111 children with multidrug-resistant tuberculosis (MDR-tuberculosis). 
